Tokyo Tape
Sign in
← Toho Holdings

Quarterly report · Q2

8129.TEDINET S100S94E
Period2023-04-01 → 2023-09-30
Filed2023-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
MetricValuePeriodScopeSource row
Revenue¥734.8bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥1.39T2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥681.5bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥6.5bn2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥5.8bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥7.9bn2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥19.2bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥7.4bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥13.0bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥6.0bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥8.8bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥13.6bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥3.6bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥8.8bn2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥3.6bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥801.4bnat 2023-09-30Cons.Assets
Total assets¥715.3bnat 2023-03-31Cons.Assets
Total assets¥740.6bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥556.2bnat 2023-09-30Cons.Liabilities
Total liabilities¥472.4bnat 2023-03-31Cons.Liabilities
Net assets / equity¥245.1bnat 2023-09-30Cons.Net assets
Net assets / equity¥242.9bnat 2023-03-31Cons.Net assets
Net assets / equity¥245.6bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥137.9bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥86.2bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥133.5bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥81.8bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥97.9bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥90.0bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥53.9bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥9m2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥10.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow¥3.5bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow¥4.3bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥407m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥5.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥13.1bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥3.0bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥134.192023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥112.262023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥196.72022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥51.012022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥21.792022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥121.192023-04-01 → 2023-09-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥180.672022-04-01 → 2023-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥46.882022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio30.6%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio33.9%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio33.1%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 46
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥29.3bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥29.3bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥1.8bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue2023-04-01 → 2023-09-30¥46.6bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue external2023-04-01 → 2023-09-30¥46.6bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥7m
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentsegment profit2023-04-01 → 2023-09-30¥895m
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue2023-04-01 → 2023-09-30¥5.2bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue external2023-04-01 → 2023-09-30¥1.2bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥4.0bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentsegment profit2023-04-01 → 2023-09-30¥436m
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue2023-04-01 → 2023-09-30¥709.4bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue external2023-04-01 → 2023-09-30¥684.8bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥24.6bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentsegment profit2023-04-01 → 2023-09-30¥6.8bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥3.0bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥2.3bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥678m
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥139m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥764.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥734.8bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥29.3bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥8.3bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥28.3bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥28.3bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥850m
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue2022-04-01 → 2022-09-30¥45.1bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue external2022-04-01 → 2022-09-30¥45.1bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3m
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentsegment profit2022-04-01 → 2022-09-30¥878m
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue2022-04-01 → 2022-09-30¥4.8bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.1bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3.7bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentsegment profit2022-04-01 → 2022-09-30¥478m
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue2022-04-01 → 2022-09-30¥656.6bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue external2022-04-01 → 2022-09-30¥632.8bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥23.8bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentsegment profit2022-04-01 → 2022-09-30¥5.1bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥3.3bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥2.5bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥782m
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥246m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥709.8bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥681.5bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥28.3bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥6.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 581
ItemContextValueUnit
Gain on sales of noncurrent assets eiPrior1YTDDuration109000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration18000000JPY
Gain on sales of investment securities eiPrior1YTDDuration20000000JPY
Gain on sales of investment securities eiCurrentYTDDuration5133000000JPY
Other eiPrior1YTDDuration19000000JPY
Other eiCurrentYTDDuration0JPY
Extraordinary incomePrior1YTDDuration149000000JPY
Extraordinary incomeCurrentYTDDuration5152000000JPY
Loss on disposal of noncurrent assets elPrior1YTDDuration74000000JPY
Loss on disposal of noncurrent assets elCurrentYTDDuration48000000JPY
Impairment loss elPrior1YTDDuration26000000JPY
Impairment loss elCurrentYTDDuration－JPY
Provision for loss on anti monopoly act elPrior1YTDDuration1400000000JPY
Provision for loss on anti monopoly act elCurrentYTDDuration－JPY
Other elPrior1YTDDuration28000000JPY
Other elCurrentYTDDuration20000000JPY
Extraordinary lossPrior1YTDDuration1529000000JPY
Extraordinary lossCurrentYTDDuration68000000JPY
Income before income taxesPrior1YTDDuration6012000000JPY
Income before income taxesCurrentYTDDuration13029000000JPY
Income taxes currentPrior1YTDDuration2801000000JPY
Income taxes currentCurrentYTDDuration5280000000JPY
Income taxes deferredPrior1YTDDuration-399000000JPY
Income taxes deferredCurrentYTDDuration-1039000000JPY
Income taxesPrior1YTDDuration2401000000JPY
Income taxesCurrentYTDDuration4241000000JPY
Profit lossPrior1YTDDuration3611000000JPY
Profit lossCurrentYTDDuration8788000000JPY
Profit loss attributable to non controlling interestsPrior1YTDDuration12000000JPY
Profit loss attributable to non controlling interestsCurrentYTDDuration6000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration3598000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration8782000000JPY
Profit lossPrior1YTDDuration3611000000JPY
Profit lossCurrentYTDDuration8788000000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration2005000000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration439000000JPY
Share of other comprehensive income of associates accounted for using equity method ociPrior1YTDDuration40000000JPY
Share of other comprehensive income of associates accounted for using equity method ociCurrentYTDDuration17000000JPY
Other comprehensive incomePrior1YTDDuration2045000000JPY
Other comprehensive incomeCurrentYTDDuration457000000JPY
Comprehensive incomePrior1YTDDuration5656000000JPY
Comprehensive incomeCurrentYTDDuration9246000000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration5643000000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration9240000000JPY
Comprehensive income attributable to non controlling interestsPrior1YTDDuration12000000JPY
Comprehensive income attributable to non controlling interestsCurrentYTDDuration6000000JPY
Income before income taxesPrior1YTDDuration6012000000JPY
Income before income taxesCurrentYTDDuration13029000000JPY
Depreciation and amortization ope cfPrior1YTDDuration2919000000JPY
Depreciation and amortization ope cfCurrentYTDDuration3098000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass